MASSIVE PLEURAL EFFUSIONS IN CANCER PATIENTS: AN EXPERIENCE FROM A TERTIARY CARE CENTRE IN INDIA

作者
Gayathri R Nair,Senthil Kumar E,K Sivasubramaniam,S G D Gangadharan
出处
期刊: 卷期号:: 39-42
标识
DOI:10.36106/ijsr/9109453
摘要

Introduction Massive pleural effusions are typically characterised by collection of 1000 ml or more uid in the pleural cavity. It may be a malignant or a nonmalignant effusion and is common in cancer patients. Aims and objectives 1. To study the clinical prole of cancer patients who develop massive pleural effusions. 2. To analyse the management of massive pleural effusions in cancer patients. Materials and methods This is a retrospective study. Records of cancer patients diagnosed to have massive pleural effusions from the month of April 2022-November 2022, in our department were analysed in December 2022. Data regarding the clinical prole and management of pleural effusion of these patients was collected and analysed. Results During the study period,32 cancer patients were diagnosed to have a massive pleural effusion, out of which 24 had a malignant pleural effusion. The most common cause of malignant pleural effusion was lung cancer (38%), followed by breast cancer (29%). Therapeutic thoracocentesis alone was done for 14 patients. Therapeutic tapping was followed by Intercostal Chest Drain (ICD) insertion for 12 patients, whereas 6 patients had an upfront ICD inserted. Elderly age, ICD insertion and the development of hospital acquired pneumonia(HAP) were associated with signicantly longer duration of hospital stay. ICD insertion was signicantly associated with the development of HAP . No signicant difference was observed in the recurrence rate between patients who underwent ICD insertion vs therapeutic thoracocentesis alone. Conclusions Upfront ICD insertion for management of massive pleural effusions in cancer patients is associated with increased rates of HAP, prolonged duration of hospital stay and no difference in the rate of recurrence of effusions, when compared to patients who underwent therapeutic thoracocentesis alone. Thus, we suggest that these patients undergo therapeutic needle thoracocentesis as the rst line of management, with an attempt to avoid ICD insertion if possible.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
情怀的应助被gao采纳,获得10
1秒前
梁林林完成签到,获得积分10
2秒前
能干涵瑶发布了新的文献求助10
2秒前
miaomiao发布了新的文献求助10
2秒前
QH_Y发布了新的文献求助20
4秒前
kermit完成签到,获得积分20
5秒前
6秒前
共享精神的应助被浅笑丶沫采纳,获得10
6秒前
小陈完成签到,获得积分10
7秒前
亦依然完成签到 ,获得积分10
7秒前
7秒前
王大哥完成签到 ,获得积分10
8秒前
橙子发布了新的文献求助10
11秒前
明亮白山完成签到 ,获得积分10
12秒前
gao发布了新的文献求助10
13秒前
14秒前
汉堡包的应助被科研通管家采纳,获得10
14秒前
CodeCraft的应助被科研通管家采纳,获得10
14秒前
爆米花的应助被科研通管家采纳,获得10
14秒前
14秒前
CHAosLoopy的应助被科研通管家采纳,获得10
15秒前
打打的应助被py2026采纳,获得10
15秒前
SciGPT的应助被科研通管家采纳,获得10
15秒前
隐形曼青的应助被科研通管家采纳,获得10
15秒前
15秒前
16秒前
16秒前
巧克力王者完成签到,获得积分10
16秒前
Echo完成签到,获得积分10
17秒前
18秒前
miaomiao完成签到,获得积分10
18秒前
喜悦的乞完成签到 ,获得积分10
18秒前
19秒前
林宝完成签到 ,获得积分10
20秒前
顺利中完成签到,获得积分10
20秒前
vavel发布了新的文献求助10
21秒前
Vanff完成签到,获得积分10
21秒前
22秒前
22秒前
fang完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Rosenblum, Global Change Biology 800
自動車の空力技術 800
Organizational Behavior 510
Management and the Arts 510
Issues in Task-Based Language Teaching 500
Geschichtliche Grundbegriffe (GGB), Band 5: Pro–Soz 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 化学工程 工程类 有机化学 物理 复合材料 生物化学 内科学 细胞生物学 基因 遗传学 免疫学 冶金 光电子学 癌症研究
热门帖子
关注 科研通微信公众号,转发送积分 7789486
求助须知:如何正确求助?哪些是违规求助? 9327178
关于积分的说明 20416392
捐赠科研通 7378781
什么是DOI,文献DOI怎么找? 3322780
关于科研通互助平台的介绍 2470726
邀请新用户注册赠送积分活动 2339612